MADRIGAL PHARMACEUTICALS, INC. (MDGL)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch MDGL
See up to 3 months of MDGL. The 7-day demo opens the 1M and 3M ranges and puts MDGL on your watchlist.
Start 7-day demoLatest MDGL insider trades
About MADRIGAL PHARMACEUTICALS, INC. (MDGL)
MADRIGAL PHARMACEUTICALS, INC. files with the SEC under CIK 0001157601 and is classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
MDGL Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 35 | 14,747 | $7.95M |
| Grant or award | 2 | 1,725 | |
| Option exercise | 2 | 100,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
MDGL insider transactions (Form 4)
20859 Form 4 filings on record, the earliest from Nov 5, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Carole Huntsman - Officer | Open-market sale | Common Stock | 120 | $548.71 footnote F4 | $66K | |
| Carole Huntsman - Officer | Open-market sale | Common Stock | 40 | $549.34 footnote F5 | $22K | |
| Carole Huntsman - Officer | Open-market sale | Common Stock | 200 | $552.38 footnote F6 | $110K | |
| Carole Huntsman - Officer | Open-market sale | Common Stock | 40 | $553.23 footnote F7 | $22K | |
| Carole Huntsman - Officer | Open-market sale | Common Stock | 120 | $556.04 footnote F8 | $67K | |
| Carole Huntsman - Officer | Open-market sale | Common Stock | 200 | $559.60 footnote F9 | $112K | |
| Carole Huntsman - Officer | Open-market sale | Common Stock | 80 | $560.62 footnote F10 | $45K | |
| Carole Huntsman - Officer | Open-market sale | Common Stock | 40 | $563.21 | $23K | |
| Carole Huntsman - Officer | Open-market sale | Common Stock | 80 | $564.57 footnote F11 | $45K | |
| Carole Huntsman - Officer | Open-market sale | Common Stock | 894 | $550.97 | $493K | |
| Carole Huntsman - Officer | Open-market sale | Common Stock | 144 | $547.27 footnote F3 | $79K | |
| ||||||
| Richard S. Levy - Director | Open-market sale | Common Stock | 645 | $517.51 footnote F4 | $334K | |
| Richard S. Levy - Director | Open-market sale | Common Stock | 835 | $518.53 footnote F5 | $433K | |
| Richard S. Levy - Director | Open-market sale | Common Stock | 1,355 | $519.67 footnote F6 | $704K | |
| Richard S. Levy - Director | Open-market sale | Common Stock | 308 | $520.68 footnote F7 | $160K | |
| Richard S. Levy - Director | Open-market sale | Common Stock | 1,094 | $521.79 footnote F8 | $571K | |
| Richard S. Levy - Director | Open-market sale | Common Stock | 1,434 | $522.70 footnote F9 | $750K | |
| Richard S. Levy - Director | Open-market sale | Common Stock | 811 | $523.66 footnote F10 | $425K | |
| Richard S. Levy - Director | Open-market sale | Common Stock | 153 | $524.49 footnote F11 | $80K | |
| Richard S. Levy - Director | Open-market sale | Common Stock | 120 | $526.68 footnote F12 | $63K | |
| Richard S. Levy - Director | Open-market sale | Common Stock | 200 | $527.85 footnote F13 | $106K | |
| Richard S. Levy - Director | Open-market sale | Common Stock | 440 | $528.60 footnote F14 | $233K | |
| Richard S. Levy - Director | Open-market sale | Common Stock | 40 | $530.21 | $21K | |
| Richard S. Levy - Director | Option exercise | Stock Option (Right to Buy) | 2,500 | $0.00 | - | |
| Richard S. Levy - Director | Option exercise | Stock Option (Right to Buy) | 6,000 | $0.00 | - | |
| Richard S. Levy - Director | Option exercise | Common Stock | 2,500 | $7.36 | $18K | |
| Richard S. Levy - Director | Option exercise | Common Stock | 6,000 | $16.46 | $99K | |
| Richard S. Levy - Director | Open-market sale | Common Stock | 146 | $514.67 footnote F2 | $75K | |
| Richard S. Levy - Director | Open-market sale | Common Stock | 919 | $515.64 footnote F3 | $474K | |
| ||||||
| Kenneth Bate - Director | Open-market sale | Common Stock | 3,259 | $481.13 footnote F2 | $1.57M | |
| Kenneth Bate - Director | Open-market sale | Common Stock | 1,284 | $482.41 footnote F3 | $619K | |
| Kenneth Bate - Director | Open-market sale | Common Stock | 2,069 | $483.41 footnote F4 | $1.00M | |
| Kenneth Bate - Director | Open-market sale | Common Stock | 1,931 | $484.78 footnote F5 | $936K | |
| Kenneth Bate - Director | Open-market sale | Common Stock | 1,008 | $485.54 footnote F6 | $489K | |
| Kenneth Bate - Director | Open-market sale | Common Stock | 827 | $486.73 footnote F7 | $403K | |
| Kenneth Bate - Director | Open-market sale | Common Stock | 2,775 | $487.49 footnote F8 | $1.35M | |
| Kenneth Bate - Director | Open-market sale | Common Stock | 696 | $489.09 footnote F9 | $340K | |
| Kenneth Bate - Director | Open-market sale | Common Stock | 933 | $489.95 footnote F10 | $457K | |
| Kenneth Bate - Director | Open-market sale | Common Stock | 30 | $490.98 footnote F11 | $15K | |
| Kenneth Bate - Director | Option exercise | Stock Option (Right to Buy) | 5,470 | $0.00 | - | |
| Kenneth Bate - Director | Option exercise | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Kenneth Bate - Director | Option exercise | Stock Option (Right to Buy) | 1,105 | $0.00 | - | |
| Kenneth Bate - Director | Option exercise | Common Stock | 5,470 | $9.45 | $52K | |
| Kenneth Bate - Director | Option exercise | Common Stock | 10,000 | $303.79 | $3.04M | |
| Kenneth Bate - Director | Option exercise | Common Stock | 1,105 | $280.04 | $309K | |
| Kenneth Bate - Director | Open-market sale | Common Stock | 1,763 | $480.24 footnote F1 | $847K | |
| ||||||
| William John Sibold - Officer | Open-market sale | Common Stock | 7,279 | $445.63 | $3.24M | |
| William John Sibold - Officer | Open-market sale | Common Stock | 6,485 | $400.03 | $2.59M | |
| William John Sibold - Officer | Open-market sale | Common Stock | 1,131 | $401.00 | $454K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 2,460 | $372.87 | $917K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 26,704 | $372.87 | $9.96M | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 675 | $374.43 | $253K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 7,325 | $374.43 | $2.74M | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 480 | $380.44 | $183K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 5,209 | $380.44 | $1.98M | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 176 | $380.78 | $67K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 1,919 | $380.78 | $731K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 873 | $381.12 | $333K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 9,477 | $381.12 | $3.61M | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 105 | $382.29 | $40K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 1,136 | $382.29 | $434K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 262 | $382.82 | $100K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 2,838 | $382.82 | $1.09M | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 373 | $383.79 | $143K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 4,049 | $383.79 | $1.55M | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 1,248 | $385.06 | $481K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 13,545 | $385.06 | $5.22M | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 409 | $387.07 | $158K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 4,441 | $387.07 | $1.72M | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 34 | $389.00 | $13K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 366 | $389.00 | $142K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 231 | $389.89 | $90K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 2,506 | $389.89 | $977K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 862 | $392.24 | $338K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 9,362 | $392.24 | $3.67M | |
| Shannon T. Kelley - Officer | Open-market sale | Common Stock | 458 | $358.66 | $164K | |
| Shannon T. Kelley - Officer | Open-market sale | Common Stock | 126 | $369.64 | $47K | |
| Shannon T. Kelley - Officer | Open-market sale | Common Stock | 84 | $370.06 | $31K | |
| Shannon T. Kelley - Officer | Open-market sale | Common Stock | 84 | $371.35 | $31K | |
| Shannon T. Kelley - Officer | Open-market sale | Common Stock | 252 | $372.44 | $94K | |
| Shannon T. Kelley - Officer | Open-market sale | Common Stock | 68 | $374.13 | $25K | |
| Shannon T. Kelley - Officer | Open-market sale | Common Stock | 190 | $375.75 | $71K | |
| Shannon T. Kelley - Officer | Open-market sale | Common Stock | 42 | $376.62 | $16K | |
| Kenneth Bate - Director | Option exercise | Common Stock | 10,000 | $16.46 | $165K | |
| Kenneth Bate - Director | Open-market sale | Common Stock | 2,317 | $363.41 | $842K | |
| Kenneth Bate - Director | Open-market sale | Common Stock | 2,516 | $364.24 | $916K | |
| Kenneth Bate - Director | Open-market sale | Common Stock | 2,567 | $365.33 | $938K | |
| Kenneth Bate - Director | Open-market sale | Common Stock | 600 | $366.14 | $220K | |
| Kenneth Bate - Director | Open-market sale | Common Stock | 1,104 | $367.63 | $406K | |
| Kenneth Bate - Director | Open-market sale | Common Stock | 896 | $368.56 | $330K | |
| Kenneth Bate - Director | Option exercise | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Paul A. Friedman - Director | Option exercise | Common Stock | 129,172 | $9.45 | $1.22M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 1,600 | $358.23 | $573K | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 455 | $359.31 | $163K | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 3,153 | $360.27 | $1.14M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 1,754 | $361.13 | $633K | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 1,439 | $362.29 | $521K | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 2,591 | $363.08 | $941K | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 3,529 | $364.02 | $1.28M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 1,716 | $365.19 | $627K | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 3,152 | $366.22 | $1.15M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 7,119 | $367.31 | $2.61M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 6,788 | $368.34 | $2.50M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 7,992 | $369.44 | $2.95M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 7,877 | $370.44 | $2.92M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 22,710 | $371.53 | $8.44M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 28,976 | $372.39 | $10.79M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 24,166 | $373.35 | $9.02M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 4,155 | $374.38 | $1.56M | |
| Paul A. Friedman - Director | Option exercise | Stock Option (Right to Buy) | 129,172 | $0.00 | - | |
 Rebecca Taub - Director | Option exercise | Common Stock | 3,200 | $9.45 | $30K | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 2,980 | $350.18 | $1.04M | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 220 | $351.02 | $77K | |
| Rebecca Taub - Director | Option exercise | Common Stock | 43,263 | $9.45 | $409K | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 3,580 | $350.87 | $1.26M | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 2,870 | $351.60 | $1.01M | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 1,175 | $352.45 | $414K | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 4,587 | $354.04 | $1.62M | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 6,479 | $354.97 | $2.30M | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 5,752 | $355.95 | $2.05M | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 4,864 | $356.88 | $1.74M | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 6,715 | $357.85 | $2.40M | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 6,541 | $358.81 | $2.35M | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 700 | $359.71 | $252K | |
| Rebecca Taub - Director | Option exercise | Stock Option (Right to Buy) | 3,200 | $0.00 | - | |
| Rebecca Taub - Director | Option exercise | Stock Option (Right to Buy) | 43,263 | $0.00 | - | |
| Paul A. Friedman - Director | Option exercise | Common Stock | 3,203 | $9.45 | $30K | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 2,903 | $350.19 | $1.02M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 300 | $351.04 | $105K | |
| Paul A. Friedman - Director | Option exercise | Common Stock | 43,605 | $9.45 | $412K | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 3,303 | $350.93 | $1.16M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 3,202 | $351.59 | $1.13M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 1,382 | $352.61 | $487K | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 4,768 | $354.06 | $1.69M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 6,546 | $355.00 | $2.32M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 5,244 | $355.97 | $1.87M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 5,094 | $356.94 | $1.82M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 8,434 | $357.93 | $3.02M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 5,032 | $358.83 | $1.81M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 600 | $359.81 | $216K | |
| Paul A. Friedman - Director | Option exercise | Stock Option (Right to Buy) | 3,203 | $0.00 | - | |
| Paul A. Friedman - Director | Option exercise | Stock Option (Right to Buy) | 43,605 | $0.00 | - | |
| Daniel J. Brennan - Director | Grant or award | Common Stock | 967 | $0.00 | - | |
| Daniel J. Brennan - Director | Grant or award | Stock Option (Right to Buy) | 1,705 | $0.00 | - | |
| Rebecca Taub - Director | Option exercise | Common Stock | 1,000 | $9.45 | $9K | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 1,000 | $350.01 | $350K | |
| Rebecca Taub - Director | Option exercise | Stock Option (Right to Buy) | 1,000 | $0.00 | - | |
| Paul A. Friedman - Director | Option exercise | Common Stock | 1,400 | $9.45 | $13K | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 1,400 | $350.03 | $490K | |
| Paul A. Friedman - Director | Option exercise | Stock Option (Right to Buy) | 1,400 | $0.00 | - | |
| Paul A. Friedman - Director | Option exercise | Common Stock | 26,176 | $9.45 | $247K | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 5,541 | $350.17 | $1.94M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 2,371 | $351.38 | $833K | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 2,110 | $352.67 | $744K | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 2,319 | $353.82 | $821K | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 6,851 | $354.65 | $2.43M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 5,784 | $355.61 | $2.06M | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 1,200 | $356.62 | $428K | |
| Paul A. Friedman - Director | Option exercise | Common Stock | 2,700 | $9.45 | $26K | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 2,000 | $350.10 | $700K | |
| Paul A. Friedman - Director | Open-market sale | Common Stock | 700 | $351.57 | $246K | |
| Paul A. Friedman - Director | Option exercise | Stock Option (Right to Buy) | 26,176 | $0.00 | - | |
| Paul A. Friedman - Director | Option exercise | Stock Option (Right to Buy) | 2,700 | $0.00 | - | |
| Rebecca Taub - Director | Option exercise | Common Stock | 26,444 | $9.45 | $250K | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 6,000 | $350.19 | $2.10M | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 1,897 | $351.37 | $667K | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 2,357 | $352.64 | $831K | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 2,569 | $353.82 | $909K | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 5,800 | $354.61 | $2.06M | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 6,441 | $355.61 | $2.29M | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 1,380 | $356.52 | $492K | |
| Rebecca Taub - Director | Option exercise | Common Stock | 2,657 | $9.45 | $25K | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 2,057 | $350.09 | $720K | |
| Rebecca Taub - Director | Open-market sale | Common Stock | 600 | $351.50 | $211K | |
| Rebecca Taub - Director | Option exercise | Stock Option (Right to Buy) | 26,444 | $0.00 | - | |
| Rebecca Taub - Director | Option exercise | Stock Option (Right to Buy) | 2,657 | $0.00 | - | |
| Kenneth Bate - Director | Grant or award | Common Stock | 715 | $0.00 | - | |
| Kenneth Bate - Director | Grant or award | Stock Option (Right to Buy) | 1,290 | $0.00 | - | |
| Richard S. Levy - Director | Grant or award | Common Stock | 715 | $0.00 | - | |
| Richard S. Levy - Director | Grant or award | Stock Option (Right to Buy) | 1,290 | $0.00 | - | |
| Paul A. Friedman - Director | Grant or award | Common Stock | 715 | $0.00 | - | |
| Paul A. Friedman - Director | Grant or award | Stock Option (Right to Buy) | 1,290 | $0.00 | - | |
| Jacqualyn A. Fouse - Director | Grant or award | Common Stock | 203 | $0.00 | - | |
| Jacqualyn A. Fouse - Director | Grant or award | Stock Option (Right to Buy) | 366 | $0.00 | - | |
| James M. Daly - Director | Grant or award | Common Stock | 715 | $0.00 | - | |
| James M. Daly - Director | Grant or award | Stock Option (Right to Buy) | 1,290 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Common Stock | 1,430 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Common Stock | 1,430 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Non- Qualified Stock Options (right to buy) | 2,580 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Non- Qualified Stock Options (right to buy) | 2,580 | $0.00 | - | |
| David Soergel - Officer | Grant or award | Common Stock | 7,545 | $0.00 | - | |
| David Soergel - Officer | Grant or award | Stock Option (Right to Buy) | 12,839 | $0.00 | - | |
| Richard S. Levy - Director | Option exercise | Common Stock | 9,470 | $65.06 | $616K | |
| Richard S. Levy - Director | Option exercise | Stock Option (Right to Buy) | 9,470 | $0.00 | - | |
| Fred B. Craves - Director | Open-market sale | Common Stock | 3,080 | $315.21 | $971K | |
| Fred B. Craves - Director | Open-market sale | Common Stock | 520 | $315.90 | $164K | |
| Fred B. Craves - Director | Open-market sale | Common Stock | 2,200 | $350.08 | $770K | |
| Fred B. Craves - Director | Open-market sale | Common Stock | 1,200 | $350.71 | $421K | |
| Carole Huntsman - Officer | Open-market sale | Common Stock | 688 | $316.92 | $218K | |
| Richard S. Levy | Option exercise | Common Stock | 5,000 | $7.36 | $37K | |
| Richard S. Levy | Open-market sale | Common Stock | 5,000 | $350.00 | $1.75M | |
| Richard S. Levy | Option exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | - | |
| Richard S. Levy | Option exercise | Common Stock | 5,000 | $7.36 | $37K | |
| Richard S. Levy | Open-market sale | Common Stock | 2,800 | $300.10 | $840K | |
| Richard S. Levy | Open-market sale | Common Stock | 1,100 | $301.22 | $331K | |
| Richard S. Levy | Open-market sale | Common Stock | 800 | $302.25 | $242K | |
| Richard S. Levy | Open-market sale | Common Stock | 300 | $304.29 | $91K | |
| Richard S. Levy | Option exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | - | |
Item 5.02, 7.01, 9.01
Item 2.02, 9.01
Item 5.02, 5.07, 9.01
Item 2.02, 9.01
Recent MDGL Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| PAUL FRIEDMAN | Director | 50,000 | $25.83M | View on EDGAR | |
| WILLIAM SIBOLD | Director, Officer | 5,221 |
MDGL insider trading FAQ
What is the latest insider trade for MDGL?
MADRIGAL PHARMACEUTICALS, INC. (MDGL) had 4 insider filings in the last 90 days, with the most recent on 2026-09-11. The full record for MDGL runs to 59 Form 4 filings, the earliest from 2024-11-05. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying MDGL stock?
No insider purchases of MDGL were filed in the last 90 days. 26 purchases are on record for this company.
How many insiders are selling MDGL stock?
35 insider sales of MDGL were filed in the last 90 days, totaling $7.95M.
Where can I see MDGL SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects MDGL Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - William John Sibold view on EDGAR
- - Shannon T. Kelley view on EDGAR
- - John C. Reed view on EDGAR
- - William John Sibold view on EDGAR
- - Rebecca Taub view on EDGAR
- - Richard S. Levy view on EDGAR
- - Jacqualyn A. Fouse view on EDGAR
- - James M. Daly view on EDGAR
- - Daniel J. Brennan view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where MDGL's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow MDGL with a 7-day demo
- MDGL on your watchlist
- Every MDGL Form 4 filing on record
- Up to 3 months of MDGL price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
